Skip to main content
. 2020 Sep 18;11:2142. doi: 10.3389/fimmu.2020.02142

Table 1.

Demographic and clinical data.

MS patients OND patients
All MS n = 42 CIS n = 23 RRMS n = 19 n = 23
Gender, males:females, (n:n) 13:29 8:15 5:14 8:15
Age at sampling, years (mean ± SD) 38.3 ± 11.7 n = 42 37.7 ± 12.6 39.1 ± 10.7 39.2 ± 13.1
MS disease duration, months [median (P25, P75)] 7 (1.8, 28) n = 42 2 (1, 8) 17 (7, 79)
EDSS at sample collection [median (P25, P75)] 1 (0, 2) n = 38 1 (1, 0.5) 1.5 (0.8, 2.1)
MSSS prior to treatment [median (P25, P75)] 2.7 (0.7, 5.2) n = 22 1.6 (0.6, 4.8) 3 (0.6, 5.2)
Number of relapses at sample collection [median (P25,P75)] 1 (1, 2) n = 42 1 (1, 1) 2 (2, 3)
Annual rate of relapses prior to treatment [median (P25,P75)] 1.2 (0.4, 3.3) n = 42 1.1 (0.4, 4.4) 1.2 (0.3, 2.5)
Period of time: last relapse - sample collection, months [median (P25,P75)] 2.5 (0.75, 6) n = 42 2 (1, 8) 3 (0, 5)
Radiological measurements Number of gadolinium enhancing lesions [median (P25,P75)] 1 (0, 3) n = 28 0 (0, 2) 1 (0, 3)
Percentage of patients with more than 10 T2 lesions (%) 83 n = 41 91.3 72.2

CIS, clinically isolated syndrome; EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; MSSS, Multiple Sclerosis Severity Scale; n, number of subjects; OND, other neurological diseases; P25, 25th percentile, P75, 75th percentile; RRMS, relapsing-remitting MS; SD, standard deviation.